MedTrace Logo

IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer

NCT06206941 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2025-10-31

No results posted yet for this study

Summary

The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety of ways to manage symptoms including traditional and alternative treatments including cannabis, acupuncture, etc. This research will have an important impact on our knowledge of cancer symptom management, and ultimately improve patient care and safety.

Participants will complete online surveys and 7 days of ecological momentary assessments at 0, 1, 2, 4, 6, 9 and 12 month to compare the cannabis users and non cannabis users symptoms.

Conditions

Sponsors & Collaborators

  • Thomas Jefferson University

    collaborator OTHER

  • Oregon Health and Science University

    collaborator OTHER

  • State University of New York at Buffalo

    lead OTHER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-02
Primary Completion
2027-09-30
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06206941 on ClinicalTrials.gov